The choice between transcatheter (TAVR) and surgical aortic valve replacement (SAVR) is one of the most complex decisions in modern cardiology. Anatomy, risk profile, valve selection, durability expectations, and concomitant disease all factor into a decision that will define your cardiac function for decades. An independent review ensures the recommendation matches your specific case — not institutional capabilities or referral patterns.
Aortic valve replacement is no longer a single-strategy procedure. The emergence of TAVR has transformed a once straightforward surgical decision into a nuanced analysis that depends on dozens of anatomical, physiological, and patient-specific variables. The recommendation you receive often depends as much on which door you walk through as on your actual clinical profile. A hospital with a high-volume TAVR program may favor transcatheter approaches. A surgical center may recommend open replacement. Neither is wrong in the abstract — but only one is right for you.
Aortic annulus dimensions, coronary height, left ventricular outflow tract calcification, peripheral vascular access, and bicuspid anatomy all determine whether TAVR is safe and effective for your specific anatomy — or whether open surgical replacement is the better path.
STS-PROM, EuroSCORE II, and frailty assessments drive the risk-benefit calculus. Low-risk patients may benefit from surgical durability data spanning decades. Intermediate and high-risk patients may benefit from the reduced recovery time and lower periprocedural risk of TAVR.
Mechanical vs. bioprosthetic, balloon-expandable vs. self-expanding, sutureless vs. conventional — each valve type carries distinct trade-offs in durability, hemodynamics, paravalvular leak rates, and anticoagulation requirements that must be matched to your life circumstances.
Surgical aortic valve replacement (SAVR) has 20+ years of durability data. Transcatheter valves have 5–10 years. For patients under 65, valve longevity and the potential need for reintervention become critical factors in the decision.
If you have concurrent coronary artery disease, mitral regurgitation, aortic aneurysm, or atrial fibrillation, the optimal approach may change. Combined procedures can be performed surgically but not always via catheter-based techniques.
Recovery timeline, activity goals, anticoagulation tolerance, and personal values all factor into this decision. A 55-year-old marathon runner and an 82-year-old with limited mobility may have identical stenosis but radically different optimal strategies.
Our Clintelligence™ AI platform and Heart Team physicians evaluate every dimension of your aortic valve disease to determine the optimal treatment strategy.
We review your pre-procedural CT, transthoracic echo, and transesophageal echo to assess annular dimensions, calcium distribution, coronary ostial height, leaflet morphology, and vascular access suitability.
STS-PROM for isolated AVR and combined AVR-CABG, EuroSCORE II, and AATS risk scores calculated from your clinical data — with predicted outcomes for mortality, stroke, renal failure, prolonged ventilation, and major morbidity.
Systematic evaluation of TAVR feasibility including access route options (transfemoral, transaxillary, transapical, transcaval), valve sizing recommendations, and risk of paravalvular leak, conduction disturbance, and coronary obstruction.
Your case mapped to 2020 ACC/AHA Valvular Heart Disease guidelines with specific class of recommendation and level of evidence for each treatment pathway — TAVR, SAVR, or continued medical surveillance.
Sentinel provider intelligence identifies centers and surgeons with the highest volumes and best outcomes for your specific procedure type — isolated AVR, AVR-CABG, or complex aortic root procedures.
The 2020 ACC/AHA guidelines for management of valvular heart disease provide a Class I recommendation for Heart Team evaluation of aortic valve disease. This means that the highest level of clinical evidence supports having both a cardiac surgeon and an interventional cardiologist independently assess your case before a treatment pathway is selected.
In practice, many patients receive a recommendation from a single specialist. A cardiologist may recommend TAVR. A surgeon may recommend open replacement. Both may be excellent physicians making reasonable recommendations — but the patient is left to reconcile two competing opinions without the clinical framework to evaluate them.
WhiteGloveMD delivers the Heart Team evaluation that guidelines mandate but real-world practice often omits. Your cardiac surgeon and cardiologist each review your records independently, with the benefit of AI-generated risk scores and guideline mapping, and co-sign a unified recommendation that weighs both surgical and interventional perspectives.
You should strongly consider a second opinion if you have been told you need aortic valve replacement and are unsure whether TAVR or open surgery is right for you, if you are under 65 and the valve choice will have decades-long implications, if you have a bicuspid aortic valve (which complicates TAVR), if you have been told you are "too high risk" for surgery, or if you have concurrent cardiac conditions requiring potential combined procedures. The decision between TAVR and SAVR is one of the most consequential in modern cardiology — and one where institutional capabilities often influence the recommendation.
TAVR (transcatheter aortic valve replacement) delivers a new valve through a catheter, typically via the femoral artery, without opening the chest. SAVR (surgical aortic valve replacement) requires a sternotomy or mini-sternotomy to directly visualize and replace the valve under direct vision. TAVR offers faster recovery (days vs. weeks), lower short-term procedural risk, and no general anesthesia requirement in some cases. SAVR offers proven long-term durability (20+ years of data), the ability to address concomitant disease, and superior hemodynamic performance in some valve sizes.
Our Clintelligence™ AI agents analyze your CT aortography, echocardiograms, and catheterization data to assess annular dimensions, calcium burden, leaflet morphology (tricuspid vs. bicuspid), coronary ostial height, LVOT geometry, and peripheral vascular access suitability. This analysis feeds into both TAVR feasibility assessment and SAVR risk stratification, providing a comprehensive picture of which approach your anatomy best supports.
Bicuspid aortic valve anatomy is present in approximately 1–2% of the population and significantly complicates the TAVR decision. The asymmetric calcification pattern, elliptical annulus, and variable raphe morphology can increase the risk of paravalvular leak, valve malposition, and aortic injury with transcatheter approaches. While experienced high-volume centers have demonstrated acceptable TAVR outcomes in selected bicuspid patients, many cases are better served by surgical replacement. Our analysis specifically assesses your bicuspid morphology type and TAVR feasibility.
WhiteGloveMD aortic valve second opinion packages start at $995 for the Report Only option, which includes full AI analysis, CT and echo review, multi-model risk scoring, TAVR feasibility assessment, and a dual-physician-signed White Glove Insights™ Report. Packages with video consultation range from $1,995 to $5,995. Visit our pricing page for full details and inaugural pricing.
Your White Glove Insights™ Report is delivered within 48 hours of receiving your complete medical records, including CT and echocardiographic imaging. Our 24 Clintelligence™ AI agents analyze your records in parallel with physician review, ensuring comprehensive analysis without delay. If your procedure is scheduled urgently, contact our team to discuss expedited turnaround.
Get an independent Heart Team evaluation of your TAVR vs. SAVR decision — with CT anatomy review, multi-model risk scoring, and guideline-based recommendations. Delivered in 48 hours.